Fatkhutdinov N.; Sproesser K.; Krepler C.; Liu Q.; Brafford P.; Herlyn M.; Aird K.; Zhang R.
(2016)
© 2016 American Association for Cancer Research.The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF inhibitors (BRAFi) ...